AML

Criteria to qualify for study:Drug used in study:
  • Relapsed of refractory AML; previously untreated AML not suitable for intensive Induction.

HR 41

A Phase 1/2, Open label, Mulitcenter 2 part study to access the safety, tolerability, Pharmaconetics, and efficacy, of AZD2811 Nanoparticle as Monotherapy or in combination in treatment – naïve or relapsed/refractory Acute Myeloid Leukemia.

Criteria to qualify for study:Drug used in study:
  • Newly diagnosed AML not previously treated or AML in remission after induction.

AML 47

A phase lb/ll Study evaluating the safety and efficacy of idasanutlin in combination with Cytarabine and Daunorubicin in patients newly diagnosed with Acute Myeloid leukemia (AML) and the safety and efficacy of Idasanutlin in the maintenance of first AML complete remission.

Criteria to qualify for study:Drug used in study:
  • No prior treatment for AML except Hydroxyurea: not eligible for treatment with standard cytarabine and anthracycline induction regimines L

AML 49

A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in combination with Azacitidine or Decitabine in an outpatient setting in AML patients ineligible for intensive chemotherapy

Criteria to qualify for study:Drug used in study:
  • First line treatment
  • Low blast count

MDS 21

Phase 3, Randomized, Controlled, Open label, Clinical Study of Pevonedistat Plus Azacitidine versus single agent Azacitidine as First-Line treatment for patients with higher risk Myelodysplatic Syndrome, Chronic Myelomonocytic Leukemia, of Low Blast Acute Myelogenous Leukemia.